Pharmacological and Clinical Heterogeneity of Anti-Amyloid Monoclonal Antibodies in Early Alzheimer's Disease: A Systematic Review and Meta-Analysis of Randomized Trials.
Level 1 - systematic review of randomized trials
Systematic review and meta-analysis of randomized controlled trials
PubMed 42506306 · doi:10.3390/medsci14030337
What was done
A systematic review and random-effects meta-analysis following PRISMA 2020 guidelines searched PubMed/MEDLINE, Embase, and Cochrane CENTRAL for phase III placebo-controlled randomized trials. Eligible trials evaluated anti-amyloid monoclonal antibodies (lecanemab, donanemab, aducanumab, and gantenerumab) in patients with biomarker-confirmed mild cognitive impairment or mild dementia due to Alzheimer's disease. The primary efficacy outcome was change from baseline in Clinical Dementia Rating-Sum of Boxes (CDR-SB) at maximum follow-up. Safety outcomes included amyloid-related imaging abnormalities with edema/effusion (ARIA-E), ARIA with hemorrhage (ARIA-H), serious adverse events, and treatment discontinuation.
What was found
Six randomized comparisons from four phase III trials (n = 7,695) were included. Anti-amyloid antibodies were associated with a statistically significant reduction in clinical progression compared with placebo (pooled mean difference in CDR-SB: -0.42 points; 95% CI: -0.59 to -0.25; I² = 78%). Efficacy was driven mainly by lecanemab and donanemab, while aducanumab showed discordant trial results and gantenerumab demonstrated no clinically meaningful benefit. The overall pooled effect approached the lower threshold of minimal clinically important difference for CDR-SB. Therapy was associated with a marked increase in ARIA-E risk (pooled risk ratio: 10.1; 95% CI: 7.8 to 13.0), though most episodes were asymptomatic and detected via MRI.
Why it matters
This review synthesizes phase III trial evidence demonstrating that while certain anti-amyloid therapies slow cognitive decline, the average clinical effect is modest, varies significantly by specific drug, and carries a high risk of ARIA requiring close safety monitoring.
Limits
Substantial statistical heterogeneity was observed across trials for the primary clinical outcome (I² = 78%). The absolute magnitude of benefit sits at the lower boundary of clinical significance. The abstract does not report long-term follow-up beyond the included trials, specific numerical estimates for ARIA-H or discontinuation rates, or individual-level biomarker clearance correlations.
Cited by
- supports Monoclonal antibodies targeting amyloid produce small changes in the disease trajectory of established early Alzheimer's disease.